Sharp at 100+? Thank You, Genes. Thank You, Immune System.
Staying lucid as a centenarian may depend on the immune system you inherit.
6493 RESULTS
Sort By:
Staying lucid as a centenarian may depend on the immune system you inherit.
Sharp at 100+? Thank You, Genes. Thank You, Immune System. In Hydrocephalus, Does Slow Drainage Cause Dementia? Differential Diagnosis: Can Synaptic Proteins Get It Done? Kuopio Alzheimer Symposium (9th) and Nordic Memory Clinic Conference (3rd)
Middle-aged people who strode 8,000+ steps a day were less likely to have a range of conditions, including diabetes and hypertension.
At a satellite of the annual meeting of the Society for Neuroscience, researchers reported big new discoveries in ALS genetics...
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
Scientists are testing passive and active immunotherapies that take down pyroglutamate Aβ, and a combo Aβ/tau vaccine.
Slow clearance of an MRI tracer offers evidence of inefficient glymph transport in the brain.
The inaugural Holloway Summit, hosted by AFTD, focused on the development of digital health technologies to track the progression of FTD’s myriad manifestations.
ADNI4 will run from 2022 to 2027 and recruit 500 new participants, at least half of whom will be from underrepresented racial and ethnic groups.
In collaboration with the Banner Alzheimer’s Institute, Eli Lilly will test the anti-amyloid immunotherapy in cognitively normal people with a high risk for AD based on plasma phospho-tau-217.
A liposomal anti-tau vaccine elicited a response against disease-linked forms of tau, outdoing a conjugated vaccine. A separate tack to vaxx against tau is waiting in the wings.
Adding to our collection of APP, Presenilin, Tau, and Trem2 mutations, the new dataset curates neurologic and non-neurologic information, ranging from clinical to molecular.
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
No filters selected